Copay Assistance for Eylea, Vabysmo, and Other AMD Injections
Help Paying for AMD Eye Injections at a Glance
If the bill for your eye injections feels out of reach, you have more options than most people know about. Help comes from four places. Drug makers offer copay cards. Charities offer grants. Drug makers also give some people the drug free. And government programs can pick up your share.
Which door is open to you depends most of all on the kind of insurance you carry. A drug maker's copay program is only for people with commercial insurance, and it is not valid for people who use a federal or state government program to pay for the medicine or the shot itself12. If you are on Medicare, an independent charity is usually your route instead.
Your retina office is the fastest way in. Ask to speak with the person who handles billing or patient assistance. That one call often does more than hours of searching on your own.
This split is not a quirk of one company. It comes from federal anti-kickback rules. Federal guidance warns drug makers that copay coupons can draw sanctions unless the maker keeps them from inducing purchases paid for by federal health programs, and it points makers who want to help people with government coverage toward donating to independent charities instead2.
The result is a two-lane system. Commercial and job-based insurance takes the manufacturer copay lane. Medicare, Medicaid, TRICARE, and VA coverage take the charity and government-help lane. Both can cut what you pay, in some cases close to nothing.
You do not need to solve the whole system today. Three steps settle most of it:
- Call your retina practice and ask for the billing or patient-assistance coordinator. Say plainly that the cost is a problem.
- Have your insurance card, your yearly household income, and your household size ready before that call.
- If you are on Medicare, ask which charitable funds for macular disease are open right now, because funds open and close through the year.
Cost is a medical issue, not just a money issue. Telling your team early gives them the most room to help.
What These Injections Cost and Why the Bills Feel So Large
These medicines are given as a tiny injection into the eye, usually every four to twelve weeks for as long as the eye needs them. Anti-VEGF medicines, a family that includes Avastin, Lucentis, and Eylea, are used for wet age-related macular degeneration, macular swelling, diabetic retinopathy, and retinal vein occlusion. Treatment improves vision in about 1 of every 3 people who receive it, and at least holds vision steady in about 9 of every 103. Vabysmo (faricimab) is a newer injection used for the same kinds of retinal swelling.
That schedule is what turns a manageable copay into a yearly burden. A cost you could absorb once becomes one you owe six to twelve times a year.
A doctor gives these injections in the office, so Original Medicare pays for them under Part B, not under a drug plan. Once you have met the yearly deductible, Part B pays 80 of every 100 dollars of the approved amount, and you owe the other 20 as coinsurance. There is no yearly cap on what you can be asked to pay4. That yearly Part B deductible is 283 dollars in 2026, and the standard Part B premium is 202.90 dollars a month5.
Here is what that looks like. If the approved amount for the drug and the visit is about 1,700 dollars, your one-fifth share is roughly 340 dollars for that visit. Repeat it eight times and you near 2,700 dollars a year, which is why the programs below exist. Your share of the retinal scan, and the cost of a ride home, sit on top of that.
Your coinsurance is a slice of the drug's price, so the drug moves your bill more than anything else. A 2017 Academy analysis put bevacizumab (Avastin) at roughly 50 to 60 dollars a dose, against roughly 1,850 dollars for aflibercept (Eylea) and roughly 1,170 to 2,023 dollars for ranibizumab (Lucentis)6. Prices move over time, so ask your practice what each option costs under your plan today. Avastin is commonly used off-label for AMD, because the FDA has not licensed it for that use7.
Price alone does not settle which drug belongs in your eye. In a large NIH trial, 1,185 people with wet AMD at 43 centers were assigned at random to Avastin or Lucentis, and vision improvement was virtually identical, within one letter on an eye chart, when either drug was given monthly7. Some eyes still do better on a longer-acting drug, and that call belongs to your retina specialist. What you can do is raise cost and ask whether a lower-priced option suits your eye.
The Four Kinds of Help, Side by Side
Nearly every source of help for AMD injections falls into one of four buckets. The table sorts them by who can use them.
| Kind of help | Who it is for | What it usually covers |
|---|---|---|
| Manufacturer copay program | People with commercial or job-based insurance only | Your copay, coinsurance, and deductible for that brand, up to a yearly limit |
| Independent charitable fund | Mainly people with Medicare or military coverage, within an income limit | A yearly grant for copays, and sometimes premiums and visit charges |
| Manufacturer patient assistance | Uninsured people, or insured people whose plan excludes the drug | The medicine itself at no cost, if you meet the income test |
| Government cost-sharing help | People with Medicare and limited income or assets | Premiums, and for some programs the deductible and coinsurance too |
These often combine, such as a charitable grant for the drug plus a Medigap policy for the rest.
Each brand runs its own program, and your retina practice usually handles enrollment. The Genentech Ophthalmology Co-pay Program, which covers Vabysmo, is open to commercially insured patients and is not valid for anyone using a federal or state program to pay for the medicine or its administration1. Regeneron runs the parallel program for Eylea at 1-855-EYLEA4U, and the retina specialists' society keeps a current list of manufacturer and independent programs with their phone numbers8.
These programs cap what they pay in a calendar year, and the cap and the fine print change. Ask for the current terms in writing when you enroll.
If you have Medicare, this is the main road. Foundations run disease-specific funds and award a yearly grant you draw against. In 2026 the two largest merged: the Patient Advocate Foundation and the PAN Foundation combined in March and launched a single program called TotalAssist on July 1, bringing nearly 150 disease funds under one roof and covering copays, coinsurance, deductibles, insurance premiums, office-visit charges on the day of treatment, and administration charges9.
The catch is money supply. The HealthWell Foundation's macular degeneration fund awards up to 4,000 dollars per twelve-month cycle to people whose insurance covers the medicine and whose household income sits at or below five times the federal poverty level. That fund is closed to new applicants at the moment because of insufficient funding, though existing grants stay active10. A closed fund is not a rejection of you. Funds reopen when donations arrive, so ask your coordinator to watch for it.
Separate from the copay programs, drug makers run foundations that supply the medicine itself at no charge. The Genentech Patient Foundation provides medicine at no cost to uninsured patients, and to insured patients whose plan does not cover the medicine, when they meet the income requirements1. Regeneron runs a comparable program for Eylea; ask the practice or call the number above for its current terms.
Ask even if you assume your income is too high, because the ceilings sit well above the poverty line.
The quietest savings often come from fixing your coverage rather than chasing a grant. A Medicare Supplement policy, also called Medigap, is bought alongside Original Medicare and pays some or all of the Part B coinsurance that would otherwise be yours, depending on which lettered plan you buy. Medicare Advantage plans work differently, with their own networks and rules, but they are required to cap what you pay out of pocket each year.
If your income and assets are limited, four Medicare Savings Programs help with Medicare costs. Under the Qualified Medicare Beneficiary program, providers are not allowed to bill you for Medicare deductibles, coinsurance, or copayments on covered services, and you apply through your state11. Full Medicaid does much the same job.
Which Route Fits Your Situation
Start with the manufacturer copay program for the drug you are on. It is the fastest and usually the most generous route for you, enrollment often takes minutes at the practice, and the benefit covers the drug and frequently the injection charge.
Check whether your employer plan routes manufacturer help through an outside program as a condition of coverage, since that can affect your eligibility later.
Skip the copay card, because federal rules close it to you, and work through two questions instead. The first is whether you have a Medigap policy or a Medicare Advantage plan that limits your yearly exposure. The second is whether an open charitable fund for macular disease is taking applications today.
Those two handle most of the cost for most people. If neither applies, a Medicare Savings Program or Medicaid is next, and a State Health Insurance Assistance Program counselor can help you apply.
Go straight to the manufacturer's patient assistance foundation. It is built for this situation and can supply the medicine itself rather than a discount. Bring proof of income, because the decision turns on the income test more than anything else.
Ask at the same time whether a lower-cost anti-VEGF drug is medically reasonable for your eye, because that conversation can change the yearly bill more than any application does.
When you have both, Medicaid generally pays the Medicare cost-sharing, so your share for injections is usually very small or nothing. Confirm that your practice bills Medicaid as your secondary coverage, because a practice not enrolled with Medicaid cannot apply that benefit.
If a bill arrives anyway, call the billing office before you pay it. Under the Qualified Medicare Beneficiary rules above, some of those bills should never have been sent.
How to Apply Without Losing Weeks
Practices that give injections all day have staff who do these applications constantly and usually know which funds are open this week. They also send the clinical information a foundation needs, the step that stalls most patient-led applications.
Ask directly: who here handles patient assistance, and can you enroll me today?
Applications ask for the same handful of things, and having them at hand turns a two-week process into a two-day one:
- Your insurance cards, including any secondary or supplement policy
- Your household size and your total yearly household income before taxes
- Your diagnosis and the name of the drug you are receiving
- Your prescriber's name and the practice's contact information
- A recent tax return or benefit statement, if income proof is requested
Charitable funds run on donations, so a fund open in March can be closed in June. That timing, not the strength of your application, is what most often decides whether a grant comes through on the first try.
So ask to be told when the fund reopens, check more than one foundation, and apply the day a fund opens. Meanwhile ask whether the practice can set up a payment plan so treatment continues while you wait.
Almost all of these programs run on a calendar year or a twelve-month cycle, and none renews itself. A grant that covered you well in one year can lapse quietly in January and become a surprise bill in February.
Put a reminder in your calendar six weeks before your grant year ends.
Limits, Risks, and a Realistic Picture of What Help Can Do
Assistance is real, but it has edges. Programs cap what they pay in a year, and most cover the drug and sometimes the visit, but not your travel or your time. A grant tied to one diagnosis will not stretch to an unrelated condition, and manufacturer programs are brand-specific, so switching drugs means a new application. Plan for those gaps rather than assuming one program erases the whole cost.
The most damaging thing cost does is quietly push people out of treatment. In a review pooling 52 studies across 24 countries and 409,215 patients, about 28 of every 100 people stopped anti-VEGF injections within 12 months. Financial burden was among the most commonly listed reasons for stopping, given by about 19 of every 100 of those who stopped or missed treatment, and stopping was far more common in a health system relying on individual payment than in one with universal coverage12.
The reason this matters is what those gaps cost. In one study of 472 people treated for AMD, those with a gap in follow-up ended with worse vision than those without, a median of about 45 letters on the eye chart against about 6413. That is one study of a group, not a forecast for you. The action is small: before you cancel or stretch out an appointment for money reasons, call the practice and say why. There is usually something to try.
For most people on injections, a workable answer exists in some mix of a copay program, a charitable grant, a supplement policy, and a lower-cost drug. It rarely arrives in one phone call, and it usually needs revisiting once a year as funds and prices shift.
That is a chore rather than a crisis. Treat affordability as a standing part of your care and it stays manageable for years.
When to Call Your Retina Practice
Serious trouble after an injection is uncommon, but a few signs need a call that day rather than at your next visit. Call your retina practice right away, or seek urgent care if you cannot reach them, if in the days after an injection you have:
- Eye pain that is getting worse rather than settling
- Vision that is dropping instead of recovering
- An eye that is becoming redder day by day
- A sudden shower of new floaters, flashing lights, or a dark curtain across your vision
To keep that in proportion: across nine studies pooling 174,159 injections, there were 88 infections inside the eye, roughly 5 for every 10,000 injections14. The reason to call anyway is that an infection inside the eye needs treatment quickly, and your team would far rather hear from you and find nothing wrong.
Some money problems are worth flagging before they turn into a missed appointment. Call the billing or assistance coordinator if your insurance changes, if a grant is about to run out, if a bill arrives that you cannot pay, or if you are thinking about skipping a visit over cost.
None of this is a reason for embarrassment. Practices deal with all of it routinely, and the earlier they hear, the more they can do.
Send your question to the right person and you get an answer faster, and when in doubt start with the coordinator at your retina practice. Your retina specialist decides which drug your eye needs and how often. The coordinator handles copay programs, charitable applications, and payment plans. Your plan settles coverage and prior authorization questions.
Common Questions About Paying for AMD Injections
No. Manufacturer copay programs are limited to people with commercial insurance and are not valid for anyone using a federal or state program, including Medicare, Medicaid, TRICARE, and VA coverage. This is a federal anti-kickback rule rather than a company preference. The route built for you instead is an independent charitable foundation, which can accept people with Medicare, plus Medigap or a Medicare Savings Program to handle your coinsurance.
It depends on your insurance and your drug. On Original Medicare with no supplement, you pay the yearly Part B deductible and then one fifth of the approved amount for each visit, which for a higher-priced drug can run a few hundred dollars per injection and a few thousand dollars per year. A Medigap policy, a charitable grant, or a lower-cost drug often drops that to a small fraction. Ask your practice for an estimate based on your plan.
Closed funds are common, and they reflect donation levels rather than anything about you. Ask your practice to check every foundation running a macular disease fund, since they open and close on different schedules, and ask to be notified the day your first choice reopens. Meanwhile ask about a payment plan, a manufacturer patient assistance application, or whether a lower-cost drug suits your eye, so treatment continues while you wait.
It is a fair question to raise, and the answer belongs to your retina specialist. Avastin costs a small fraction of the newer drugs, and a large NIH trial found it and Lucentis equally effective at preserving vision over two years in wet AMD. Even so, some eyes respond better to a longer-acting drug, and your doctor weighs your scans and your response. Raise cost openly as a factor rather than switching or stopping on your own.
It varies by program, which is why it is worth asking specifically. Some charitable funds cover copays, coinsurance, deductibles, insurance premiums, office-visit charges on the day of treatment, and administration charges. Manufacturer copay programs usually cover the drug and often the injection charge, but little else. When you enroll, ask which line items the program pays, then compare that against bills you have already received.
Charitable grants and manufacturer assistance are not loans and are not reported to credit agencies, so they do not touch your credit, and applying for a Medicare Savings Program or Medicaid does not affect it either. If you receive other needs-based benefits, ask the foundation or a benefits counselor how a grant would be counted. Also check whether an employer plan has rules about outside assistance, since a few do.
More Questions About Assistance Programs and Coverage
Possibly, but it is a trade-off rather than an obvious win. Medicare Advantage plans carry a yearly limit on out-of-pocket costs that Original Medicare does not, and that limit helps when you need frequent injections. In exchange you accept a network, referral rules, and prior authorization, and your retina specialist may not be in that network. Talk it through with a State Health Insurance Assistance Program counselor before an enrollment period.
Yes, several things. Income limits differ between foundations and adjust for household size and sometimes for high-cost areas, so being over one fund's line does not mean being over all of them. Beyond that, a Medigap policy, a manufacturer copay program if your insurance is commercial, a lower-cost drug, and a payment plan all work independently of income. Ask your coordinator to walk through them with you.
Call the practice before the appointment and say exactly that. Missing injections is the outcome everyone is trying to avoid, and practices have levers you do not: emergency charitable funds, manufacturer assistance, payment plans, and sometimes a lower-cost drug. Pausing treatment on your own is the option most likely to cost you vision, so make the call even if it feels awkward. The conversation is routine for them.
A few focused questions turn a rushed visit into a plan. Consider asking:
- Which drug am I on, and what does my share of each injection cost under my plan?
- Is a lower-cost anti-VEGF drug medically reasonable for my eye, and what would we give up?
- Who in this practice handles patient assistance, and can you enroll me today?
- Which charitable funds for macular disease are open right now, and can you apply for me?
- Does my assistance cover the office visit and the imaging, or only the drug?
- When does my current grant or copay benefit end, and who reminds me to renew it?
- Genentech Pro (Genentech, Inc.) (2026). VABYSMO (faricimab-svoa) financial assistance options.
- U.S. Department of Health and Human Services, Office of Inspector General (2014). Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons.
- American Academy of Ophthalmology, EyeSmart (2025). Anti-VEGF Treatments.
- Medicare.gov (Centers for Medicare and Medicaid Services) (2026). Medicare costs: what you pay for Part B services.
- Centers for Medicare and Medicaid Services newsroom fact sheet (2026). 2026 Medicare Parts A and B Premiums and Deductibles.
- American Academy of Ophthalmology, EyeNet (2017). Expensive Drugs (EyeNet Magazine).
- National Eye Institute, National Institutes of Health (CATT trial) (2012). NIH study finds Avastin and Lucentis are equally effective in treating age-related macular degeneration.
- American Society of Retina Specialists (2026). Patient Assistance Resources for Retina Patients.
- Patient Advocate Foundation and PAN Foundation (2026). Patient Advocate Foundation launches TotalAssist, the nation's largest charitable patient assistance program.
- HealthWell Foundation (2026). Macular Degeneration Fund.
- Medicare.gov (Centers for Medicare and Medicaid Services) (2026). Medicare Savings Programs.
- Systematic Reviews (BMC), peer-reviewed (PMC10237080) (2023). Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis.
- Diagnostics (MDPI), peer-reviewed (PMC10887977) (2024). Understanding Loss to Follow-Up in AMD Patients Receiving VEGF Inhibitor Therapy: Associated Factors and Underlying Reasons.
- Journal of Ophthalmology, peer-reviewed (PMC4892688) (2016). Antibioprophylaxis in Prevention of Endophthalmitis in Intravitreal Injection: A Systematic Review and Meta-Analysis.